Abbott’s ADHD drug too risky, FDA warns

The of liver damage from Abbott Laboratories’ discontinued attention-de ; cit drug Cylert and its generic risk pemoline counterparts make the drug too dangerous for the U.S. market, the Food and Drug Administration says. Agency of;cials stopped short of recalling the drug that has been on the market since 1975. Instead, the FDA said Cylert will remain available until supplies run out, and doctors “ should transition their patients to an alternative therapy.” In March, Abbott said itwould no longer make the drug, but critics had argued that it was too dangerous to be sold.